Q1 show in line; earnings recovery from Q2 key



Consumer Goods >

Result Update > August 01, 2025

CMP (Rs): 416 | TP (Rs): 475

We maintain a positive stance on ITC with ADD and a Jun-26E SOTP-based target price of Rs475, as we believe most headwinds are now in the base. Q1FY26 profit was in line with expectations, supported by stable performance in the cigarettes business (revenue up 7.7% with an estimated 6.5% volume growth). Non-cigarette revenue grew 22% YoY, led by a strong 39% growth in the agri business. However, weak margins in other FMCG and the paper segment resulted in an 11% YoY decline in non-cigarette EBIT. Looking ahead, we expect gradual improvement in cigarette performance, driven by improved execution and a catch-up in volume growth relative to the industry-containing market share loss will be key. That said, a near-term overhang persists due to potential cig tax increases linked to the replacement of the compensation cess.

Cigarette business (37% of net sales/84% of EBIT) had an in-line show

Cigarette revenue grew 7.7% YoY (stood in line) with ~6.5% volume growth (vs 5% estimate). Differentiated and premium portfolio continues to drive overall growth. Sequential growth acceleration is heartening, but likely to be lower than industry growth, implying steady market share loss. Innovation, portfolio fortification, and recent launches have been like Q4, where we see a focus on execution. We expect a near-term overhang of tax hikes with replacement of GST compensation cess. We largely maintain estimates, where we shift part of the growth from realization to volume. Segment EBIT margin came in at 71.1%, moderated by 270bps YoY and 80bps QoQ. Segment EBIT grew 3.7% YoY. We expect high costs for leaf tobacco to enter the base from Q2 and expect moderate margin expansion from Q3FY26. We continue to see 10% EBIT CAGR over FY25-28E.

Non-cig portfolio continues to hurt the overall show

Non-cigarettes revenue saw 22% revenue growth YoY, aided by 39% growth in the agri business. Adj for agri, revenue grew 6%. Driven by weakness in the paper and other FMCG businesses, non-cigarette business EBIT fell 11% YoY in Q1. Other FMCG sales grew ~5.2%, with pressure seen in notebooks (ex-Notebook, revenue grew 8.6%). Other FMCG EBITDA declined 16.5% YoY, given a 180bps contraction in OPM to 9.4% in Q1 (up 50 bps QoQ). Digital first and organic portfolio is clocking Rs10bn ARR. The company now generates ~6% of revenue from Quick Commerce channel (50% of ecommerce). Agri business saw an improvement in topline with 39% revenue growth, aided by strong growth in leaf tobacco exports. Segment EBIT grew 22% YoY, with 60bps margin contraction to 4.5%. Paper business saw 7% growth, driven by volume growth, though margin weakness (down by 550bps YoY to 7.7%) caused a 38% EBIT decline.

Valuation to factor improving outlook; share losses in cig a concern

While we see optical performance improvement ahead, steady share loss in cigarettes and expectation of tax increases on cigarettes linked to replacement of compensation cess are likely to keep valuation in check in the near term.

ITC: Financial Snapshot (Standalone)									
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E				
Revenue	654,251	693,223	781,478	893,571	1,003,002				
EBITDA	244,629	240,236	265,823	313,548	349,480				
Adj. PAT	199,453	195,627	213,643	243,542	270,174				
Adj. EPS (Rs)	16.0	15.6	17.0	19.3	21.3				
EBITDA margin (%)	37.4	34.7	34.0	35.1	34.8				
EBITDA growth (%)	2.2	(1.8)	10.7	18.0	11.5				
Adj. EPS growth (%)	6.4	(2.1)	8.6	13.4	10.4				
RoE (%)	28.5	27.9	30.7	32.9	33.7				
RoIC (%)	55.4	55.1	58.8	63.0	65.5				
P/E (x)	26.1	14.8	24.5	21.6	19.6				
EV/EBITDA (x)	19.7	20.0	18.1	for Toom 15.4	hito Margue				
P/B (x)	7.2	This report	is intended	for Team 6.9	hite Marque				
FCFF yield (%)	2.8	4.3	2.9	4.1	4.4				

Source: Company, Emkay Research

Target Price – 12M	Jun-26
Change in TP (%)	-
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	14.2

Stock Data	ITC IN
52-week High (Rs)	500
52-week Low (Rs)	390
Shares outstanding (mn)	12,523.6
Market-cap (Rs bn)	5,215
Market-cap (USD mn)	59,587
Net-debt, FY26E (Rs mn)	(357,558.7)
ADTV-3M (mn shares)	18
ADTV-3M (Rs mn)	8,294.4
ADTV-3M (USD mn)	94.8
Free float (%)	100.0
Nifty-50	24,565.3
INR/USD	87.5

Share	hol	ding,	Jun-25
-------	-----	-------	--------

Promoters (%)	0.0
FPIs/MFs (%)	38.0/46.9

Price Performa	nce		
(%)	1M	3M	12M
Absolute	0.3	(2.2)	(10.8)
Rel. to Nifty	4.3	(3.1)	(9.2)

1-Year share price trend (Rs)




Nitin Gupta nitin.aupta@emkavalobal.com +91-22-66121257

Q1FY26 performance

Exhibit 1: Q1FY26 performance							
Y/E Mar (Rs mn)	1QFY26	1QFY25	YoY (%)	4QFY25	QoQ (%)	Emkay est	Var (%)
Total income	197,499	163,734	20.6	172,482	14.5	183,670	7.5
Cost of goods	100,724	71,259	41.4	78,121	28.9	86,302	16.7
Employee expenses	9,155	8,637	6.0	8,694	5.3	9,300	(1.6)
Other expenses	25,008	22,971	8.9	25,803	(3.1)	25,000	0.0
EBITDA	62,613	60,868	2.9	59,864	4.6	63,068	(0.7)
EBITDAM (%)	31.7	37.2	-550bps	34.7	-300bps	34.3	-260bps
Depreciation	3,653	3,554	2.8	3,565	2.5	3,700	(1.3)
EBIT	58,960	57,314	2.9	56,299	4.7	59,368	(0.7)
EBITM (%)	29.9	35.0	-520bps	32.6	-280bps	32.3	-250bps
Interest cost	129	83	55.2	85	51.9	90	43.7
Other income	6,621	6,985	(5.2)	7,955	(16.8)	6,950	(4.7)
PBT	65,451	64,216	1.9	64,169	2.0	66,228	(1.2)
Tax	16,328	16,017	1.9	15,421	5.9	16,557	(1.4)
Tax rate(%)	24.9	24.9	0.0	7.3	241.4	25.0	-0.2
Adj PAT	49,124	48,199	1.9	48,747	0.8	49,671	(1.1)
Non-recurring items	0	975	(100.0)	146,869	(100.0)	0	#DIV/0!
Reported PAT	49,124	49,175	(0.1)	195,616	(74.9)	49,671	(1.1)
NPM (%)	24.9	30.0	-520bps	113.4	-8850bps	27.0	-220bps
EPS (Rs)	3.9	3.9	1.8	3.9	0.7	4.0	(1.4)


Source: Company, Emkay Research


Exhibit 2: Cigarettes – Gross revenue growth



Source: Company, Emkay Research

Exhibit 3: Cigarettes - Volume growth






Source: Company, Emkay Research

■Cig EBIT margin (on net sales)

Exhibit 5: Cigarettes - EBIT margin (on net sales)



Source: Company, Emkay Research

Exhibit 6	5:	Estimated	per	stick	analysis
-----------	----	------------------	-----	-------	----------


(Rs/stick)	1QFY26A	1QFY25	YoY
MRP sales (Rs)	8.47	8.40	1%
Retailers margin (Rs)	0.77	0.76	1%
Actual price to retailer	7.70	7.64	1%
Distributor margin	0.17	0.17	1%
GST	0.02	0.02	0%
Cess	0.05	0.05	1%
Actual price to distributor	7.46	7.40	1%
GST	0.95	0.94	1%
Cess	3.13	3.11	0%
Gross realization to company	3.39	3.35	1%
Excise	0.00	0.00	0%
NCCD	0.51	0.50	1%
Net realization to company	2.87	2.84	1%
Gross profit	2.51	2.56	-2%
Overheads	0.46	0.46	2%
Ebit	2.05	2.10	-3%
Ebit margin on gross sales	60.4%	62.6%	-225bps
Ebit margin on net sales	71.1%	73.8%	-271bps

Source: Company, Emkay Research

Exhibit 7: ITC's quarterly cigarette portfolio actions

	Q1FY26/Q4FY25	Q3FY25	Q2FY25	Q1FY25
Innovations	Classic Connect	Classic Connect	Classic Connect	Classic Connect
	American Club Clove Mint			
	Gold Flake Indie Mint			
		Uni Klov	Uni Klov	Uni Klov
				Gold Flake SLK
				Classic Icon
Portfolio Fortification	Scissors	Scissors	Scissors	Gold Flake Neo SMART Filter
	Flake Spl	Flake Spl	Flake Spl	Bristol Deluxe
	Silk Cut Red	Silk Cut Red	Silk Cut Red	Flake XL
		Classic Burst Portfolio	Classic Burst Portfolio	Flake Skipper
Recent introductions	Classic Clove	Classic Clove		
	Classic Icon	Classic Icon	Classic Icon	Classic Icon Kings
	Gold Flake Social Red	Gold Flake Social Red	Gold Flake Social Red	
	Gold Flake Social 2-Pod	Gold Flake Social 2-Pod	Gold Flake Social 2-Pod	
	Gold Flake Indie Clove	Gold Flake Indie Clove		
	Gold Flake SLK Range	Gold Flake SLK Range	Gold Flake SLK	Gold Flake North Star
	Gold Flake Nova	Gold Flake Nova	Bristol Maja Mix	Bristol Maja Mix
	American Club Just Clove	American Club Just Clove	Gold Flake Tango Mix	Gold Flake Tango Mix
	American Club Super Slims			
	Player's Aromix	Player's Aromix		
	Flake Insta Fresh	Flake Insta Fresh		
	Wave Boss	Wave Boss		
	Capstan Clove	Gold Flake North Star		
	Flight	Flight	Flight	Flight
	Scissors Super Mix			

Exhibit 8: Non-cigarette revenue growth



Source: Company, Emkay Research

Exhibit 9: Non-cigarette EBIT growth






Exhibit 10: Non-cigarette EBIT margin




Source: Company, Emkay Research

Exhibit 11: Other FMCG revenue growth




Source: Company, Emkay Research

Exhibit 12: Other FMCG EBITDA growth




Source: Company, Emkay Research

Exhibit 13: Other FMCG EBITDA margin



Source: Company, Emkay Research

Exhibit 14: Agri-business revenue growth trend




Q2FY20
Q4FY21
Q2FY21
Q2FY21
Q4FY21
Q4FY21
Q4FY22
Q4FY22
Q4FY23
Q4FY23
Q4FY23
Q4FY23
Q4FY24
Q2FY24
Q2FY25
Q4FY25
Q4FY26
Q4

Source: Company, Emkay Research

Exhibit 16: Agri-business EBIT margin ■Agri business EBIT margin 15% 13% 10% %9 8% 5% 3% 0% Q1FY25 Q1FY23 **22FY22** 33FY22 34FY22 **22FY23 23FY23** Q1FY24 22FY25

Source: Company, Emkay Research

Exhibit 17: Paper business revenue growth



Source: Company, Emkay Research

Exhibit 18: Paper business EBIT growth





Exhibit 19: Paper business EBIT margin



Source: Company, Emkay Research

Valuation

Exhibit 20: SOTP-based target price

Segment	Valuation methodologies	Unit (Rs bn)	Jun-27 est	Multiple (x)	Rs/share		
Cigarette	PE	EPS	13.96	17.0	237		
Other FMCG	EV/Sales	Sales	260,945	5.5	115		
Agri	EV/Sales	Sales	294,968	2.0	47		
Paper	EV/EBITDA	EBITDA	24,958	5.0	10		
ITC infotech	PE	EPS	0.66	30.0	20		
Net cash		Actual		1.0	31		
ITC Hotel (40% stake; with 20% hol	ding company discount)				12		
Fair value					472		
Target price	Target price						

Source: Company, Emkay Research

Exhibit 21: Changes to our estimates

	New estimates			Old estimates			Changes to our estimates		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	781,478	893,571	1,003,002	783,080	893,995	1,002,008	0%	0%	0%
growth (%)	12.7%	14.3%	12.2%	13.0%	14.2%	12.1%			
EBITDA	265,823	313,548	349,480	269,092	315,146	350,419	-1%	-1%	0%
growth (%)	10.7%	18.0%	11.5%	12.0%	17.1%	11.2%			
EBITDA margin (%)	34.0%	35.1%	34.8%	39.1%	40.9%	40.9%			
Adj PAT	213,643	243,542	270,174	216,102	244,985	271,216	-1%	-1%	0%
growth (%)	9.2%	14.0%	10.9%	10.5%	13.4%	10.7%			
EPS	17.0	19.3	21.3	17.2	19.4	21.3	-1%	-1%	0%

Source: Company, Emkay Research

Exhibit 22: Key assumptions

	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Profit and loss account									
Cigarette revenue growth	2%	-4%	15%	20%	8%	7%	8%	9%	9%
FMCG revenue growth	2%	3%	12%	20%	9%	6%	7%	9%	9%
Hotel revenue growth	9%	-66%	105%	101%	16%	-94%	10%	10%	10%
Agri revenue growth	9%	23%	29%	12%	-13%	25%	19%	20%	19%
Paper revenue growth	4%	-8%	36%	19%	-8%	1%	26%	27%	10%
Cigarette volume growth	-1%	-13%	16%	20%	3%	4%	6%	5%	5%
Earnings growth	21%	-14%	15%	23%	6%	76%	-40%	13%	10%
Cigarette PBIT growth	2%	-14%	17%	21%	6%	5%	8%	11%	10%
FMCG PBIT growth	2%	-11%	17%	22%	8%	4%	9%	13%	11%
Hotel PBIT growth	-11%	-439%	-66%	-396%	39%	21%	-19%	43%	10%
Agri PBIT growth	2%	4%	26%	29%	-6%	18%	23%	23%	23%
Paper PBIT growth	5%	-16%	55%	35%	-40%	-34%	28%	61%	18%
Gross margin	62%	56%	53%	56%	59%	54%	54%	54%	53%
A&P spends as a % of sales	2%	3%	2%	2%	2%	2%	2%	2%	2%
EBITDA margin	39%	34%	34%	36%	37%	35%	34%	35%	35%
Adj EPS (Rs/Sh)	12.42	10.59	12.22	15.02	15.98	15.63	16.98	19.26	21.26
DPS (Rs/Sh)	5.73	15.13	10.99	15.50	13.75	14.35	15.00	16.00	18.00
Balance sheet									
Avg. ROCE (%)	27%	23%	29%	34%	32%	33%	36%	40%	41%
Avg. RoE (%)	25%	21%	25%	29%	29%	29%	31%	33%	34%
Inventory days (no of)	64	76	65	59	70	79	75	75	75
Receivable days (no of)	17	17	13	13	18	21	21	21	21
Payable days (no of)	28	33	27	24	25	24	25	25	25

ITC: Standalone Financials and Valuations

Profit & Loss					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	654,251	693,223	781,478	893,571	1,003,002
Revenue growth (%)	(0.9)	6.0	12.7	14.3	12.2
EBITDA	244,629	240,236	265,823	313,548	349,480
EBITDA growth (%)	2.2	(1.8)	10.7	18.0	11.5
Depreciation & Amortization	16,478	14,419	14,951	16,670	16,796
EBIT	228,150	225,817	250,872	296,878	332,684
EBIT growth (%)	2.4	(1.0)	11.1	18.3	12.1
Other operating income	6,591	7,715	8,634	9,667	10,634
Other income	35,383	34,543	33,628	28,285	30,449
Financial expense	457	364	400	440	484
PBT	263,076	259,996	284,100	324,723	362,649
Extraordinary items	(76)	156,317	0	0	0
Taxes	63,622	64,370	70,457	81,181	92,476
Minority interest	0	0	0	0	0
Income from JV/Associates	-	-	-	-	-
Reported PAT	199,378	351,944	213,643	243,542	270,174
PAT growth (%)	6.4	76.5	(39.3)	14.0	10.9
Adjusted PAT	199,453	195,627	213,643	243,542	270,174
Diluted EPS (Rs)	16.0	15.6	17.0	19.3	21.3
Diluted EPS growth (%)	6.4	(2.1)	8.6	13.4	10.4
DPS (Rs)	13.8	14.4	15.0	16.0	18.0
Dividend payout (%)	86.1	51.0	88.3	83.1	84.7
EBITDA margin (%)	37.4	34.7	34.0	35.1	34.8
EBIT margin (%)	34.9	32.6	32.1	33.2	33.2
Effective tax rate (%)	24.2	24.8	24.8	25.0	25.5
NOPLAT (pre-IndAS)	172,974	169,909	188,655	222,658	247,849
Shares outstanding (mn)	12,485	12,514	12,579	12,644	12,709

Source: Company, Emkay Research

Cash flows					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	227,693	225,453	250,472	296,438	332,200
Others (non-cash items)	(5,677)	(167,377)	0	0	0
Taxes paid	(56,829)	(58,446)	(70,457)	(81,181)	(92,476)
Change in NWC	7,374	(30,678)	6,265	(6,614)	(16,258)
Operating cash flow	161,182	167,510	201,631	225,754	240,746
Capital expenditure	(26,016)	41,493	(64,000)	(28,000)	(28,725)
Acquisition of business	0	0	0	0	0
Interest & dividend income	20,069	20,063	33,628	28,285	30,449
Investing cash flow	21,276	1,415	(30,372)	(29,715)	(29,001)
Equity raised/(repaid)	14,428	7,973	65	65	65
Debt raised/(repaid)	(127)	886	60	81	85
Payment of lease liabilities	0	(2,439)	0	0	0
Interest paid	(457)	(364)	(400)	(440)	(484)
Dividend paid (incl tax)	(196,061)	(174,967)	(179,577)	(188,687)	(202,306)
Others	(334)	1,253	0	0	0
Financing cash flow	(182,550)	(167,656)	(179,852)	(188,980)	(202,639)
Net chg in Cash	(93)	1,269	(8,593)	7,059	9,106
OCF	161,182	167,510	201,631	225,754	240,746
Adj. OCF (w/o NWC chg.)	153,809	198,188	195,366	232,367	257,004
FCFF	135,166	209,003	137,631	197,754	212,021
FCFE	154,778	228,703	170,860	225,599	241,986
OCF/EBITDA (%)	65.9	69.7	75.9	72.0	68.9
FCFE/PAT (%)	77.6	65.0	80.0	92.6	89.6
FCFF/NOPLAT (%)	78.1	123.0	73.0	88.8	85.5

Source: Company, Emkay Research

Balance Sheet					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	12,485	12,514	12,579	12,644	12,709
Reserves & Surplus	709,848	666,487	700,553	755,409	823,277
Net worth	715,116	673,583	707,714	762,635	830,567
Minority interests	-	-	-	-	-
Non-current liab. & prov.	20,837	25,564	27,609	29,817	32,203
Total debt	681	1,568	1,627	1,709	1,794
Total liabilities & equity	746,289	706,132	742,368	799,579	869,983
Net tangible fixed assets	250,215	194,466	243,515	254,845	266,774
Net intangible assets	0	0	0	0	0
Net ROU assets	-	-	-	-	-
Capital WIP	10,870	10,707	10,707	10,707	10,707
Goodwill	-	-	-	-	-
Investments [JV/Associates]	23,936	23,936	23,936	23,936	23,936
Cash & equivalents	385,629	367,779	359,186	396,245	436,075
Current assets (ex-cash)	195,408	237,786	244,941	266,003	296,936
Current Liab. & Prov.	126,987	133,960	145,335	157,575	169,864
NWC (ex-cash)	68,422	103,826	99,606	108,428	127,072
Total assets	746,289	706,132	742,368	799,579	869,983
Net debt	(384,948)	(366,211)	(357,559)	(394,536)	(434,281)
Capital employed	746,289	706,132	742,368	799,579	869,983
Invested capital	318,637	298,292	343,121	363,273	393,846
BVPS (Rs)	57.9	54.3	56.7	60.7	65.8
Net Debt/Equity (x)	(0.5)	(0.5)	(0.5)	(0.5)	(0.5)
Net Debt/EBITDA (x)	(1.6)	(1.5)	(1.3)	(1.3)	(1.2)
Interest coverage (x)	576.3	716.3	711.5	739.3	750.6
RoCE (%)	37.7	37.1	40.8	43.8	45.2

Source: Company, Emkay Research

Valuations and key Ratios						
Y/E March	FY24	FY25	FY26E	FY27E	FY28E	
P/E (x)	26.1	14.8	24.5	21.6	19.6	
EV/CE(x)	6.7	7.1	6.7	6.3	5.7	
P/B (x)	7.2	7.7	7.3	6.9	6.3	
EV/Sales (x)	7.4	7.0	6.2	5.4	4.9	
EV/EBITDA (x)	19.7	20.0	18.1	15.4	13.8	
EV/EBIT(x)	21.1	21.3	19.2	16.2	14.5	
EV/IC (x)	15.1	16.1	14.0	13.3	12.2	
FCFF yield (%)	2.8	4.3	2.9	4.1	4.4	
FCFE yield (%)	3.0	4.4	3.3	4.3	4.6	
Dividend yield (%)	3.3	3.4	3.6	3.8	4.3	
DuPont-RoE split						
Net profit margin (%)	30.5	28.2	27.3	27.3	26.9	
Total asset turnover (x)	0.9	1.0	1.1	1.2	1.2	
Assets/Equity (x)	1.0	1.0	1.0	1.0	1.0	
RoE (%)	28.5	27.9	30.7	32.9	33.7	
DuPont-RoIC						
NOPLAT margin (%)	26.4	24.5	24.1	24.9	24.7	
IC turnover (x)	2.1	2.2	2.4	2.5	2.6	
RoIC (%)	55.4	55.1	58.8	63.0	65.5	
Operating metrics						
Core NWC days	38.2	54.7	46.5	44.3	46.2	
Total NWC days	38.2	54.7	46.5	44.3	46.2	
Fixed asset turnover	1.5	1.6	1.8	1.8	1.9	
Opex-to-revenue (%)	21.4	19.6	19.6	18.8	18.4	

Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
30-Jun-25	416	475	Add	Nitin Gupta
24-Jun-25	414	475	Add	Nitin Gupta
09-Jun-25	423	475	Add	Nitin Gupta
23-May-25	436	475	Add	Nitin Gupta
24-Apr-25	430	450	Add	Nitin Gupta
28-Mar-25	410	450	Add	Nitin Gupta
21-Mar-25	406	490	Add	Nitin Gupta
17-Mar-25	408	490	Add	Nitin Gupta
18-Feb-25	405	490	Add	Nitin Gupta
07-Feb-25	431	490	Add	Nitin Gupta
02-Feb-25	463	520	Add	Nitin Gupta
03-Jan-25	456	520	Add	Nitin Gupta
25-Oct-24	456	520	Add	Nitin Gupta
02-Oct-24	488	520	Add	Nitin Gupta

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of August 01, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of August 01, 2025
- 5. EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the August 01, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

	· J ·····
Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.